adozelesin

Adozelesin is an experimental antitumor small molecule belonging to the duocarmycin class of antibiotics. It is a synthetic cyclopropylpyrroloindole (CPI) analog of CC-1065 that acts as a potent DNA alkylating agent. The drug binds covalently to the minor groove of double-stranded DNA, specifically at A-T-rich sequences, which results in the inhibition of DNA replication and transcription. Developed primarily by Upjohn (now Pfizer), adozelesin was evaluated in Phase 1 and Phase 2 clinical trials for various cancers, including melanoma, sarcoma, and lung carcinoma, but development was ultimately discontinued. Additionally, it has been researched for potential anti-malarial properties due to its high affinity for A-T-rich DNA sequences characteristic of the Plasmodium genome.

Other names

adolezesin